title: Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
abstract: Interleukin 2 receptor is expressed not only on the surface of activated T or B lymphocytes, but also on certain lymphoid malignancies. The receptor is released from the cell membrane as soluble form (sIL-2R). Serum sIL-2R level is a sensitive and quantitative marker of circulating peripheral blood mononuclear cell activation or specific tumor cell growth including non-Hodgkin's lymphoma (NHL). However, the relevance of serum sIL-2R levels relating to clinical outcome in adult patients with NHL remains uncertain. Therefore, we investigated the serial serum sIL-2R levels in 28 untreated patients with NHL to evaluate its correlation with clinical characteristics. High serum sIL-2R level (>1000 U/ml) at diagnosis was associated with a high incidence of treatment failure (p=0.03) and poor overall survival (p=0.057). The serum sIL-2R levels decreased significantly after achieving complete remission (p=0.003). Further larger studies are required to evaluate whether serum sIL-2R level is an independent prognostic factor or not. However, adding this parameter to those already employed in the International Prognostic Index would perhaps provide a better prognostic index for adult patients with NHL.
authors.affiliation: Department of Hematology, International Medical Center of Japan, Tokyo.
authors.forename: N
authors.initials: N
authors.lastname: Kono
authors.forename: Y
authors.initials: Y
authors.lastname: Kanda
authors.forename: R
authors.initials: R
authors.lastname: Yamamoto
authors.forename: A
authors.initials: A
authors.lastname: Chizuka
authors.forename: M
authors.initials: M
authors.lastname: Suguro
authors.forename: T
authors.initials: T
authors.lastname: Hamaki
authors.forename: C
authors.initials: C
authors.lastname: Arai
authors.forename: T
authors.initials: T
authors.lastname: Matsuyama
authors.forename: N
authors.initials: N
authors.lastname: Takezako
authors.forename: A
authors.initials: A
authors.lastname: Miwa
authors.forename: A
authors.initials: A
authors.lastname: Togawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007564:Japan; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D015375:Receptors, Interleukin-2